MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
MetaVia reported preclinical tissue distribution data showing DA-1726-derived radioactivity is slowly absorbed, broadly distributed, and retained at the highest levels in adipose (fat) tissue, with prolonged retention through the final 144-hour assessment — a profile consistent with once-weekly dosing. CEO Hyung Heon Kim said the findings provide mechanistic support for the drug's differentiated profile, building on Phase 1 data in which the 48 mg dose produced a mean 9.8 cm reduction in waist circumference after eight weeks of treatment. Only minimal radioactivity reached the central nervous system, consistent with the limited brain penetration expected of peptide therapies.
Key figures
- Drug Name
- DA-1726
- Phase Of Trial
- Phase 1
- Dosing regimen
- once-weekly subcutaneous
- Upcoming readouts
- ["16-week topline data expected Q4 2026","24-week topline results expected Q1 2027"]
- Tissue retention hours
- 144
- Waist reduction context
- mean reduction at 48 mg dose after 8 weeks (Day 54) in Phase 1 study
- Waist circumference reduction cm
- 9.8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.